[Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis].

Abstract

Rheumatoid arthritis (RA) is a' disease conferring high risk for cardiovascular events (CVE). Systemic inflammation underlying RA favors development of CVE. The safety of biological agents, acting on the cardiovascular system has been inadequately investigated. On the one hand, they decrease RA activity and, on the other, may increase the risk of CVE. This… (More)
DOI: 10.17116/terarkh201688593-101

Topics

Cite this paper

@article{Popkova2016Interleukin6IA, title={[Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis].}, author={Tatiana V Popkova and Diana S Novikova and Eugeny L. Nasonov}, journal={Terapevticheskii arkhiv}, year={2016}, volume={88 5}, pages={93-101} }